Frequency of endophthalmitis following intravitreal bevacizumab injection using povidone-iodine vs povidone-iodine with topical antibiotics as prophylaxis in patients of macular oedema

Muhammad Itban  Jamil; Najam Iqbal  Ahmed; Maham  Javed; Bushra  Ashraf; Roshaan  Bint Amjad; Sana  Akhtar

doi:10.54112/bcsrj.v6i1.1514

Authors

Muhammad Itban Jamil Department Of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
Najam Iqbal Ahmed Department Of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
Maham Javed Department Of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
Bushra Ashraf Department Of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
Roshaan Bint Amjad Department Of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan
Sana Akhtar Department Of Ophthalmology, Sir Ganga Ram Hospital Lahore, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i1.1514

Keywords:

Endophthalmitis, Intravitreal Bevacizumab, Povidone Iodine

Abstract

This study compared povidone-iodine alone versus povidone-iodine with antibiotics to prevent endophthalmitis after intravitreal bevacizumab injections for macular oedema. It aimed to find the best infection prevention method. Objective: To determine the efficacy of per-operative 5% povidone-iodine alone vs combined per-operative 5% povidone-iodine with topical antibiotics for reducing the frequency of endophthalmitis in patients undergoing repeated intravitreal injection of Anti-VEGF (Bevacizumab). Methods: This randomised control trial was conducted at the Department of Ophthalmology, Sir Ganga Ram Hospital, Lahore. Patients meeting inclusion criteria were enrolled after taking informed written consents, and two equal groups were made on a random basis using a lottery method: Group A (Povidone Iodine Alone) and Group B (Povidone Iodine with Topical Antibiotics). The procedure was performed per the hospital's standard protocol, and variables were noted for data analysis. Results: The mean age was 51.23±12.43 years, with a balanced gender ratio (52.6% male, 47.4% female). Injections were predominantly in the right eye (52.9%) versus the left (47.1%). Diabetic macular oedema (57.4%) was most prevalent, followed by choroidal neovascularization (17.1%), central retinal vein occlusion (8.9%), branch retinal vein occlusion (10.9%), and other pathologies (5.7%). Groups A and B had similar baseline characteristics (p>0.05). Both groups had a 0.6% endophthalmitis rate (p=1.000), each with 175 patients. Conclusion: This study comparing 5% povidone-iodine alone versus 5% povidone-iodine with topical antibiotics for prophylaxis during intravitreal bevacizumab injections did not demonstrate a significant difference in the incidence of endophthalmitis between the two groups.

Downloads

No metrics available.

see details

References

Shrestha R, Karki P, Joshi SN. Outcome of intravitreal bevacizumab injection without pre and postoperative antibiotics. BMC Ophthalmol. 2020;20(1):1-4.

Li T, Sun J, Min J, Zhou S, Zhu X, Jia H, et al. Safety of receiving anti–vascular endothelial growth factor intravitreal injection in office-based vs operating room settings: a meta-analysis. JAMA Ophthalmol. 2021;139(10):1080-8.

Blom K, Bragadóttir R, Sivertsen MS, Moe MC, Jørstad ØK. Rewriting committee for the post-injection endophthalmitis study group, et al.: the influence of universal face mask use on endophthalmitis rifsk after intravitreal anti-vascular endothelial growth factor injections Ophthalmology. 2022;129(5):e61-2.

Bavinger JC, Yu Y, VanderBeek BL. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019;39(10):2004-11.

Ton NS, Goncharov V, Zapata I, Adam MK. Endophthalmitis after Anti-VEGF intravitreal injections with aqueous chlorhexidine versus povidone–iodine as ocular antiseptics. Ophthalmol Retina 2024;8(6):521-6.

Tanaka K, Shimada H, Mori R, Kitagawa Y, Onoe H, Tamura K, et al. Safety measures for maintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during the COVID-19 pandemic. J Clin Med. 2022;11(3):876-81.

Glassman AR, Wells III JA, Josic K, Maguire MG, Antoszyk AN, Baker C, et al. Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (Protocol T Extension Study). Ophthalmology. 2020;127(9):1201-10.

O’Callaghan RJ. The pathogenesis of Staphylococcus aureus eye infections. Pathogens. 2018;7(1):9-11.

Gonzalez-Gonzalez LA, Knickelbein JE, Doft BH, Balasubramani GK, Wisniewski SR. Incidence and visual outcomes of acute endophthalmitis post intravitreal injection of anti-vascular endothelial growth factors in a single referral center. Retina. 2022;43(3):867-76.

Xia J, Lyons RJ, Lin MY, Khalifa YM, LaRock CN. Combination of lidocaine gel and povidone–iodine to decrease acquired infections in procedures performed using topical anesthesia. J Cataract Refract Surg. 2020;46(7):1047-50.

Torres-Costa S, Ramos D, Brandão E, Carneiro Â, Rosas V, Rocha-Sousa A, et al. Incidence of endophthalmitis after intravitreal injection with and without topical antibiotic prophylaxis. European Journal of Ophthalmology. 2020;31(2):600-6.

Storey PP, Patel D, Garg S. Endophthalmitis following intravitreal injection of anti-vascular endothelial growth factor agents. Can J Ophthalmol. 2020;55(4):286-92.

Teberik K, Eski MT, Çalışkan E, Kılınçel Ö, Kaya M, Ankaralı H. Effects of topical azithromycin, moxifloxacin, and povidone iodine on conjunctival bacterial flora in patients undergoing intravitreal injection. Arq Bras Oftalmol. 2019;82(1):25-31.

Levinson JD, Garfinkel RA, Berinstein DM, Flory M, Spellman FA. Timing of povidone-iodine application to reduce the risk of endophthalmitis after intravitreal injections. Ophthalmol Retina. 2018;2(7):654-8.

Ali W, Abbasi KZ, Raza A. Panretinal photocoagulation plus Intravitreal Bevacizumab versus Panretinal photocoagulation alone for proliferative diabetic retinopathy. J Coll Physicians Surg Pak. 2018;28(12):923-7.

Javed MA, Latif S, Javaid RM, Khan AA, Mahju TM, Ahmed F. Prophylaxis of macular edema with preoperative intravitreal bevacizumab in patients with diabetic retinopathy undergoing phacoemulsification. Pak J Med Health Sci. 2022;16(03):737-9.

Saigol HK, Akbar S, Rauf A, Chauhan K, Saeed S, Tayyab H. Evaluation of vitreous cellular activity following per-operative povidone-iodine alone and combined per-operative povidone-iodine with topical antibiotic after intravitreal injection of anti-vascular endothelial growth factor bevacizumab for retinal pathologies. Egypt J Ophthalmol. 2021;1(3):168-75.

Saeed LC, Iqbal Z, Shahid L, ul Ain Q, Ishaq M. Measurement of intraocular pressure following 0.05 ml (1.25 mg) intravitreal injection of bevacizumab (avastin) to determine the rationale of using post-injection iop lowering medication: measurement of intraocular pressure. Pak Armed Forces Med J. 2013;63(1):4-8.

Bhatt SS, Stepien KE, Joshi K. Prophylactic antibiotic use after intravitreal injection: effect on endophthalmitis rate. Retina. 2011;31(10):2032-6.

Iqbal U, Malik IQ, Imtiaz HS, Ali F, Hanif A. Comparison of role of pre injection topical antibiotic and per operative one drop of 5% povidone-iodine in conjunctival sac, before giving intra-vitreal injection of anti-VEGF, in prevention against acute endophthalmitis. Ophthalmol Pak. 2019;9(03):32-6.

Baudin F, Benzenine E, Mariet AS, Ghezala IB, Bron AM, Daien V, Gabrielle PH, Quantin C, Creuzot-Garcher C. Topical antibiotic prophylaxis and intravitreal injections: impact on the incidence of acute endophthalmitis-a nationwide study in France from 2009 to 2018. Pharmaceutics. 2022;14(10):2133-44.